Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
British Journal of Cancer|October 19, 2020
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort studySaur Hajiev, Elias Allara, Leila Motedayеn Aval, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2015
Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid TumorsRohini Sharma, Kumar G Kallur, Jin S Ryu, et al.
Journal of Hepatology|September 29, 2016
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinomaDavid J Pinato, Rohini Sharma, Elias Allara, et al.
Cancers|July 14, 2023
Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort StudyShuell De Souza, Jeffrey Kahol de Jong, Ylenia Perone, et al.
International Ophthalmology|July 3, 2020
Current role of intravitreal injections in Irvine Gass syndrome-CRIIG studyAshish Sharma, Francesco Bandello, Anat Loewenstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
The New England Journal of Medicine|October 22, 2025
Belzutifan for Advanced Pheochromocytoma or ParagangliomaCamilo Jimenez, Mikkel Andreassen, Alice Durand, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative StudySuraiya Dubash, Tara D Barwick, Kasia Kozlowski, et al.
Pageof 17